The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with 123I-5-I-R91150 SPECT.
OBJECTIVE
Involvement of the serotonergic system in impulsive aggression has been demonstrated in both human and animal studies. The purpose of the present study was to investigate the effect of citalopram hydrobromide (a selective serotonin re-uptake inhibitor) on the 5-HT(2A) receptor and brain perfusion in impulsive-aggressive dogs by means of single-photon emission computed tomography.


METHODS
The binding index of the radioligand (123)I-5-I-R91150 was measured before and after treatment with citalopram hydrobromide in nine impulsive-aggressive dogs. Regional perfusion was measured with (99m)Tc-ethyl cysteinate dimer (ECD). Behaviour was assessed before treatment and again after 6 weeks of treatment.


RESULTS
A correlation was found between decreased binding and behavioural improvement in eight out of nine dogs. The 5-HT(2A) receptor binding index was significantly reduced after citalopram hydrobromide treatment in all cortical regions but not in the subcortical area. None of the dogs displayed alterations in perfusion on the post-treatment scans.


CONCLUSIONS
This study supports previous findings regarding the involvement of the serotonergic system in impulsive aggression in dogs in general. More specifically, the effect of treatment on the 5-HT(2A) receptor binding index could be demonstrated and the decreased binding index correlated with behavioural improvement.
Peremans
K
K
Department of Medical Imaging, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium. kathelijne.peremans@ugent.be
Audenaert
K
K
Hoybergs
Y
Y
Otte
A
A
Goethals
I
I
Gielen
I
I
Blankaert
P
P
Vervaet
M
M
van Heeringen
C
C
Dierckx
R
R
D000374:Aggression / Q000187:drug effects; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D015283:Citalopram / Q000008:administration & dosage*; D004285:Dogs; D007175:Impulsive Behavior / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism*; D010880:Piperidines / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism*; D058830:Serotonin 5-HT2 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D016896:Treatment Outcome
D015283:Citalopram; D010880:Piperidines; D019275:Radiopharmaceuticals; D044402:Receptor, Serotonin, 5-HT2A; D058830:Serotonin 5-HT2 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; C504893:5-iodo-R 91150
Psychopharmacology (Berl). 2002 Jan;159(3):266-74
11862359
Neurosci Lett. 1994 Apr 25;171(1-2):183-6
8084487
Psychopharmacology (Berl). 2003 Apr;167(1):72-8
12632246
Physiol Behav. 2003 Nov;80(2-3):327-31
14637232
Am J Psychiatry. 1998 Apr;155(4):543-7
9546002
Psychopharmacology (Berl). 1999 Jun;144(3):279-81
10435395
Neuropharmacology. 2000 Jan 28;39(3):471-81
10698013
Vet Clin North Am Small Anim Pract. 1997 May;27(3):479-95
9170631
Arch Gen Psychiatry. 1996 Jun;53(6):537-43
8639037
Biol Psychiatry. 2000 Mar 15;47(6):548-56
10715361
J Neuroendocrinol. 2003 Feb;15(2):150-60
12535157
Biol Psychiatry. 1999 Jun 15;45(12):1572-9
10376117
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jul;25(5):1125-44
11444681
Psychopharmacology (Berl). 2003 May;167(3):304-14
12677356
Brain Res. 2003 Jun 20;976(1):22-9
12763618
Neuroscience. 1999;92(1):327-41
10392854
Arq Neuropsiquiatr. 2001 Sep;59(3-A):499-503
11588625
Psychopharmacology (Berl). 1997 Sep;133(1):99-101
9335087
Arch Gen Psychiatry. 1994 Jan;51(1):20-7
7506515
Nucl Med Commun. 2002 Oct;23 (10 ):1019-27
12352602
Neuroscience. 1987 Apr;21(1):123-39
3601071
Eur J Nucl Med. 2001 Feb;28(2):175-82
11303887
J Am Vet Med Assoc. 1996 Nov 1;209(9):1585-7
8899022
Psychopharmacology (Berl). 1999 Mar;143(1):24-8
10227076
Brain Res. 2002 Nov 8;954(2):173-82
12414100
Neuropsychopharmacology. 2002 Sep;27(3):421-9
12225699
J Nucl Med. 1998 Jan;39(1):208-14
9443763
Br J Psychiatry. 1998 Sep;173:236-41
9926100
J Neurosci. 1999 Dec 1;19(23):10494-501
10575045
Am J Psychiatry. 2001 Jan;158(1):78-85
11136637
Brain Res. 1985 Nov 4;346(2):231-49
4052777
Am J Psychiatry. 2001 Jun;158(6):899-905
11384897
Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1538-46
14579095
Pharmacol Biochem Behav. 1991 Dec;40(4):751-6
1816562
Eur J Nucl Med. 1997 Oct;24(10 ):1253-60
9323266
Brain Res. 1991 Sep 20;559(2):181-90
1794096
Vet Radiol Ultrasound. 2001 Nov-Dec;42(6):562-8
11768526
Psychiatry Res. 2003 Jul 15;119(1-2):11-24
12860356
Naunyn Schmiedebergs Arch Pharmacol. 1995 Aug;352(2):141-8
7477436
J Clin Psychopharmacol. 2002 Aug;22(4):400-5
12172340
Arch Gen Psychiatry. 1997 Dec;54(12 ):1081-8
9400343
Prog Neuropsychopharmacol Biol Psychiatry. 2000 Apr;24(3):419-38
10836490
Eur J Nucl Med. 1995 Jul;22(7):699-710
7498234
Brain Res. 1996 Apr 1;714(1-2):57-64
8861609
Neuropsychopharmacology. 2001 Apr;24(4):370-8
11182532
J Clin Psychiatry. 2003 Jan;64(1):81-5
12590628
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1393-404
12502029
Neuropsychopharmacology. 1996 Feb;14(2):77-81
8822529
Physiol Behav. 2003 Sep;79(4-5):719-24
12954414
J Clin Psychopharmacol. 2001 Feb;21(1):53-8
11199948
Eur J Pharmacol. 1995 Dec 29;294(2-3):721-6
8750738